Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What Not To Do: FDA Reviewer Talks Cancer Drug Development Mistakes

Apr 21 2014

• By Emily Hayes

Related Content

AstraZeneca Faslodex Is First Launch For Doubled Oncology Sales Force

Apr 29 2002

Pharmacometrics Can Guide Further Trials, Minimize Risks – FDA Analysis

Oct 03 2005

Pharmacometric Reviews Increasingly Influence FDA Regulatory Decisions

Apr 15 2007

Cancer Trials Should Show Minimum 20% Overall Survival Benefit, ASCO Suggests

Apr 25 2013

Can <em>Zytiga </em>Prevail In Pre-Chemo Prostate Cancer Without Proof Of Survival Benefit?

Dec 17 2012

COPD Patient-Reported Outcome Questionnaire Is Early Example of FDA Drug Development Tool “Approval” Process

Jan 21 2014

Incyte’s Jakafi Gets Additional Claim Based On Patient-Reported Outcomes

Nov 21 2011

FDA Drug Development Tool Guidance Leaves Door Open For Advisory Committee Reviews

Nov 15 2010

Related Companies

AstraZeneca PLC

AVEO Pharmaceuticals, Inc.

Incyte Corporation

Additional Topics

United States Clinical Trials Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window